SLC5A2 and chronic kidney disease: SGLT2-is reduce overall cardiovascular events [8], heart failure [9], and chronic kidney disease [10]; GLP-1 RAs benefit overall cardiovascular events, but not heart failure [11], with some showing significant reductions in stroke and myocardial infarction [12].